Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial.
J Drugs Dermatol
; 6(3): 299-306, 2007 Mar.
Article
en En
| MEDLINE
| ID: mdl-17373192
ABSTRACT
The Experience Diagnosing, Understanding Care, and Treatment with Enbrel (EDUCATE) trial is a phase IV, 24-week, multicenter, open-label study of etanercept 50 mg weekly in the treatment of psoriatic arthritis (PsA) in community dermatology clinics. In this study, patients with active PsA and moderate to severe plaque psoriasis have measurable uses of healthcare resources at baseline, reflecting a burden of illness. Etanercept significantly reduced healthcare resource utilization, absenteeism, and caregiver assistance in PsA patients after 24 weeks of treatment. These results could translate into savings on both direct and indirect costs and improvements in health-related quality of life for patients with PsA.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Inmunoglobulina G
/
Artritis Psoriásica
/
Receptores del Factor de Necrosis Tumoral
/
Factores Inmunológicos
Tipo de estudio:
Clinical_trials
/
Health_economic_evaluation
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Drugs Dermatol
Asunto de la revista:
DERMATOLOGIA
Año:
2007
Tipo del documento:
Article
País de afiliación:
Estados Unidos